Black Diamond Therapeutics remains undervalued despite recent share price gains, with a promising EGFR inhibitor pipeline ...

Zipalertinib's NDA submission is based on promising efficacy data from the REZILIENT1 trial, showing a 35.2% ORR and ...

Targeted cancer therapies like CDK4/6, EGFR, VEGFR, and BRAF inhibitors may increase long-term kidney dysfunction risk. Learn ...

Andamertinib showed promising efficacy in NSCLC patients with EGFR exon 20 mutations, achieving a 42.7% ORR in the 240-mg cohort.

This article was reviewed by Felix Gussone, MD. What Is Biomarker Testing? How It Works and Why It Matters for Men’s Health ...

One-year program includes diet, exercise, stress relief, and physician consultations. Glycemic control and other markers ...

Breast cancer is a highly heterogeneous malignancy among women worldwide. Traditional prognostic models relying solely on ...

GISTs are solid tumors, primarily in the stomach, characterized by KIT and EGFR mutations, with Gleevec as a key treatment.

Researchers at The Johns Hopkins Medicine say they have developed a new electronic medical records-based tool that should ...

Sangamo Therapeutics (SGMO) stock rises as the U.S. FDA accepts a rolling submission request for the firm's ST-920 gene ...

Some lung cancers manage to overcome a targeted drug therapy despite it showing initial success. Yale researchers have now ...

BioDlink and Lepu Biopharma celebrated the launch of MEIYOUHENG®, the world's first EGFR-Targeting ADC, and their partnership ...